DIHYDROERGOCRISTINE

SynDRA canonical compound SYN0020335 — structure-anchored drug synonym record

Clinical phase	Launched
Primary target(s)	ADRA1A \| ADRB1 \| DRD1 \| DRD2 \| DRD3 \| DRD4 \| DRD5 \| HTR1A \| HTR2A \| HTR3A \| HTR4 \| HTR5A \| HTR6 \| HTR7
Mechanism of action	adrenergic receptor antagonist \| prolactin inhibitor
Indication	cerebrovascular insufficiency \| senile dementia
Disease area	neurology/psychiatry

All known targets

9,10-dihydroergocristine
dihydroergocristin
dihydroergocristine mesylate
dihydroergocristine mesilate
GNF-PF-3462
Nehydrin
BRD-K97440753
9,10-Dihydroergocristine
DHEC
GNF-Pf-3462
Dihydroergocristin
05D48LUM4Z
CHEMBL601773
CHEBI:59912
NCGC00017401-02
(6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
Erotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-(1-methylethyl)-5'-(phenylmethyl)-, (5'alpha,10alpha)-
(10alphaH)-5'alpha-benzyl-12'-hydroxy-3',6',18-trioxo-2'-(propan-2-yl)-9,10-dihydroergotaman
CAS-17479-19-5
Ergocristine, 9,10-dihydro-
CCRIS 4027
EINECS 241-493-4
UNII-05D48LUM4Z
SR-01000075381
NCGC00163163-01
Prestwick0_000562
Prestwick1_000562
Prestwick2_000562
Prestwick3_000562
Dihydroergocristine (BAN)
Lopac0_000409
BSPBio_000344
SCHEMBL146691
SPBio_002563
BPBio1_000380
DTXSID3046322
DIHYDROERGOCRISTINE [VANDF]
HMS2090H10